Immunovaccine Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. ImmunoVaccine is developing T cell activating cancer immunotherapies based on its patented immuno stimulating technology platform, which provides controlled and prolonged delivery of immuno stimulating agents to the immune system. ImmunoVaccine has advanced two T cell activation therapies for cancer through phase human clinical trials, and is currently conducting a phase b with Incyte Corp. and a phase study with Merck as a combination therapies in ovarian cancer. The Corporation also have an ongoing combination trial in diffuse large B cell lymphoma with Merck. These studies assessing lead candidate, DPX Survivac. The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus RSV , and currently has clinical projects ongoing to assess the potential of DepoVax to address malaria and the Zika virus. Connect at www.imvaccine.com.
Quote | Immunovia AB (OTCMKTS:IMMVF)
Last: | $0.15 |
---|---|
Change Percent: | 0.0% |
Open: | $0.15 |
Close: | $0.15 |
High: | $0.15 |
Low: | $0.15 |
Volume: | 325 |
Last Trade Date Time: | 02/08/2024 03:00:00 am |
News | Immunovia AB (OTCMKTS:IMMVF)
2024-02-21 12:47:41 ET More on Immunovia Financial information for Immunovia Read the full article on Seeking Alpha For further details see: Immunovia reports Q4 results
2023-11-09 12:09:00 ET More on Immunovia Financial information for Immunovia For further details see: Immunovia reports Q3 results
Message Board Posts | Immunovia AB (OTCMKTS:IMMVF)
Subject | By | Source | When |
---|---|---|---|
Immunovaccine releases DPX-Survivac clinical results Published on Thursday http | PennyStock Alert | investorshub | 09/16/2019 12:47:30 PM |
IMMVF reverse split 1 for 3.2 shares effective | TenKay | investorshub | 05/10/2018 1:52:41 AM |
Immunovaccine's Lead Immuno-Oncology Candidate to Enter Investigator-Sponsored | xr_biotech_consult | investorshub | 05/16/2017 3:56:28 PM |
EPS for ImmunoVaccine Inc. (IMV) Expected At $-0.02 | John-Knee | investorshub | 05/05/2017 2:24:12 AM |
ImmunoVaccine Inc. (IMV) Insider Buys C$10,800.00 in Stock | John-Knee | investorshub | 05/04/2017 11:04:25 AM |
News, Short Squeeze, Breakout and More Instantly...
Immunovia AB Company Name:
IMMVF Stock Symbol:
OTCMKTS Market:
Immunovia Publishes Interim Report for January-March 2023 PR Newswire LUND, Sweden , May 23, 2023 /PRNewswire/ -- January- March 2023 Net sales amounted to kSEK 520 (182) divided by sales of tests kSEK 379 (122) and royalties kSEK 141(60). N...
Immunovia, Inc. market access increases when achieving Clinical Laboratory Permits from Pennsylvania and Maryland Departments of Health making IMMray™ PanCan-d test available in 48 US states PR Newswire LUND, Sweden , May 23, 2022 /PRNewswire/ -- T...
Immunovia reiterates its road to reimbursement for the IMMray™ PanCan-d test PR Newswire LUND, Sweden , April 22, 2021 /PRNewswire/ -- Immunovia is launching its IMMray™ PanCan-d test in the US as a Laboratory Developed Test (LDT) in Q2 2021. The ...